Samsung Biologics

President and CEO John Rim leads the firm's strategic direction, including capacity expansion, site acquisitions, and R&D investments. Major capital allocation decisions — such as the Samsung Life Science Fund or the purchase of the Rockville facility from GSK — are made within the broader Samsung Group governance framework, where Samsung C&T and Samsung Electronics hold board representation as 43% and 31% shareholders, respectively.

The firm sources clients through direct commercial teams and C-suite relationships cultivated by Samsung Group's leadership across Asia, North America, and Europe. Dual-shore manufacturing capacity — Songdo for Asian supply and Rockville, Maryland for U.S. supply — removes logistics barriers for Western biopharma firms. Confirmed clients include AstraZeneca, Eli Lilly, and GlaxoSmithKline.

Samsung Biologics is a pure-play contract development and manufacturing organization (CDMO) with no internal drug pipeline. This structural separation means clients retain full ownership of their intellectual property, eliminating the conflict-of-interest risk present in vertically integrated pharma companies that both manufacture drugs and develop their own competing molecules.

As a corporate investor, Samsung Biologics primarily deploys capital into tangible industrial assets — biomanufacturing plants in Songdo and Rockville, technology platforms for ADCs and mRNA, and organoid-based research services. It also co-invests in life-science opportunities through the Samsung Life Science Fund alongside Samsung C&T, though the fund's specific portfolio breakdown is not publicly detailed.

Samsung Biologics is a standalone subsidiary within Samsung Group, publicly listed on the Korea Exchange. Samsung C&T holds 43.06% and Samsung Electronics holds 31.22% of shares, making them the dominant corporate parents. The group relationship provides balance-sheet strength and creditworthiness without directly managing day-to-day CDMO operations.

The firm operates a corporate social responsibility program branded as 'Enabling People' and follows formal ESG reporting under its Governance framework, including board-level oversight of compliance and sustainability. In May 2025, it was named to the Dow Jones Sustainability World Index for the fifth consecutive year.

Acquired from GlaxoSmithKline, the Rockville, Maryland facility gave Samsung Biologics its first U.S.-based drug-substance manufacturing footprint. The move created a dual-shore supply capability — Incheon for Asian and global supply, Rockville for North American clients — and signaled a strategy of acquiring Western assets to complement organic Korean capacity expansion.